J0180Agalsidase beta injection
Published CMS Medicare Part B payment-limit context for J0180, with recent quarterly history and calculated package-level strength context from the CMS crosswalk.
CMS payment limit
$232.72
per 1 MG · Medicare Part B
Up 2.3%from $227.58 in 2026-Q2
- Current quarter
- Billing unit
Payment limit over time
$234.1033$221.4557
2024-Q4: $223.522; 2025-Q1: $223.517; 2025-Q2: $222.839; 2025-Q3: $230.262; 2025-Q4: $230.154; 2026-Q1: $230.319; 2026-Q2: $227.58; 2026-Q3: $232.72
No current FDA shortage matchThe latest completed FDA data has no affected record matching the Agalsidase Beta ingredient family (FDA data as of August 20, 2026).
Fabrazyme
Package figures are calculated from the CMS per-unit payment limit × billable units per package; they are not CMS-published package-level payment limits.
Presentation updates
Put another code on your radar.
Browse the CMS directory for published payment-limit context across drugs, NDCs, and source-backed HCPCS Level II drug codes.